-
Light Horse Therapeutics Partners with Novartis in First-in-Class Drug Development
•
US-based Light Horse Therapeutics Inc., a small molecule drug developer that recently emerged from the Inception Incubator with a USD 62 million Series A funding, has struck a strategic partnership with Swiss pharmaceutical giant Novartis (NYSE: NVS). The collaboration aims to identify and develop potentially first-in-class therapeutics using Light Horse’s…
